TATAA researchers support our customers with assay design, technologies, products, and unique solutions that enable processes that reduce costs and enhance reliability in bringing their products and treatments to the clinics.
Researchers behind TATAA were among the pioneers developing quantitative real-time PCR and later single-cell, multiway, intracellular, and multimodal profiling. The DeltaAmp assay design to assess degradation, exogeneous spike-in controls to assess inhibition, ValidPrime and Alu-assays to assess contamination, interplate calibrators to eliminate inter-run variation, and reference gene panels are among the tools developed to ascertain highest possible quality of the measured data.
Short nucleic acids such as microRNAs are way too short to be targeted by two conventional primers required for PCR. Current methods therefore extend short nucleic acid targets by some means prior to amplification. This, however, compromises the sensitivity and the specificity of the assay. TATAA has found a solution. In Two-Tailed PCR a single molecule, designed with a hair-pin structure, hybridizes with both its termini, referred to as hemiprobes, to the target. Each hemiprobe alone is too short to bind but being part of the same molecule binding is cooperative and their combined affinity is sufficient. This leads to greater sensitivity but also superior specificity as sequence variation has much greater impact in the short hemiprobe binding region.
Genetic testing is typically performed on venous blood samples collected at the Doctor’s office and sent to a central laboratory that extracts and analyses the DNA. Results are sent to the Doctor, who prescribes drugs and treatment to their patient based on the results. TATAA’s Direct Blood Genotyping (“DBG”) allows genetic testing to be performed at the Point of Care at the Doctor’s office with no extraction needed. Furthermore, capillary blood is sufficient, making the entire process simple and convenient.